No Data
12 Health Care Stocks Moving In Wednesday's Intraday Session
Palisade Bio, Inc. Announces Poster Presentation at Digestive Disease Week 2026 Featuring PALI-2108 Data on Ulcerative Colitis
Wolfe Research Initiates Coverage On Palisade Bio With Outperform Rating, Announces Price Target of $7
Wolfe Research Initiates Palisade Bio(PALI.US) With Buy Rating, Announces Target Price $7
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB)